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Coxsackievirus B3 is the main cause of human viral myocarditis and cardiomyopathy. Virally
encoded Coxsackievirus 3C protease (3Cpro) plays an essential role in viral proliferation. Here,
benserazide was discovered as a novel inhibitor from a drug library screen targeting
Coxsackievirus 3Cpro using a FRET-based enzyme assay. Benserazide, whose chemical structure has
no electrophilic functional groups, was characterized as a non-competitive inhibitor by enzyme
kinetic studies. A molecular docking study with benserazide and its analogs indicated that a novel
putative allosteric binding site was involved. Speciﬁcally, a 2,3,4-trihydroxybenzyl moiety was deter-
mined to be a key pharmacophore for the enzyme’s inhibitory activity. We suggest that the putative
allosteric binding site may be a novel target for future therapeutic strategies.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Human coxsackieviruses (CVs) belong to the picornavirus
family [1] of non-enveloped positive-sense single-stranded RNA
viruses [2]. Among them, Coxsackievirus B3 (CVB3) is the most
common cause of human viral myocarditis [3,4]. Acute myocarditis
typically results in heart failure in children and adolescents
and often progresses to chronic myocarditis and dilated cardiomy-
opathy. Annually, approximately 50% of the symptoms of viral
myocarditis after heart transplants are caused by CVB3 infections
[4,5].
Upon viral infection, the positive-strand RNA genome of CVB3 is
released to the host cell and translated into a large poly-protein
precursor that undergoes a successive proteolytic cleavage process
to generate 7 functional viral proteins (2A, 2B, 2C, 3A, 3B, 3C, and
3D) and 4 structural proteins (VP1–VP4) [6,7]. The proteolytic pro-
cessing of the poly-protein is essential for the production of the
components of virions, which are primarily generated by two
virally encoded proteases, 2A and 3C [8]. The picornavirus 3C
protease in particular is an essential multifunctional protein that
Interpreting the parameters
Vmax the maximum enzyme velocity without inhibitor,
expressed in the same units as Y
Km the Michaelis–Menten constant, expressed in the same
units as X
Ki the inhibition constant, expressed in the same units as I
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events that occur during viral replication [9] but also for targeting
several host proteins such as eukaryotic translation initiation fac-
tor G and cleavage stimulation factor 64 to halt host protein syn-
thesis and induce apoptosis [10–12]. The essential roles of this
protease in virus replication have drawn attention as attractive tar-
gets for the development of antiviral therapeutic agents because
effective therapeutic strategies for the prevention or treatment of
diseases caused by CVB3 infection are not currently available
[13,14].
There are many picornavirus 3C protease and 3C like protease
inhibitors developed by many research groups in the previous
studies [13–20,23–30]. Among them, a variety of CVB3 3C protease
inhibitors have been recently reported from both the screening of
compound libraries and the design of compounds based on the
structure of the substrate acting at the active site [15]. Although
numerous 3C protease inhibitors have been developed as thera-
peutic agents for CVB3 infections, no antiviral drugs have been
approved to date for the treatment of CVB3 infections in humans
[16]. For example, compound 1 (TG-0204998 in Ref. [17]) is a pep-
tidomimetic inhibitor (Ki = 0.8 lM) interacting at the active site of
CVB 3Cpro, whose binding mode was determined by crystallization
[17]. Compound 2 (43146 in Ref. [18]) was discovered from ran-
dom screening as a non-peptide multifunctional inhibitor
(IC50 = 5.4 lM) against CVB3 3Cpro, EV71 3Cpro and SARS-CoV
3CLpro [18]. Our group has reported peptidomimetic inhibitor 3
(9e in Ref. [6]) (IC50 = 130 nM), which is an AG7088 derivative with
the lactam ring modiﬁed into a glutamine residue and the ethyl
ester group modiﬁed into an isoquinoline moiety [6]. The
a,b-unsaturated carbonyl compounds such as 1 and 3 are known
to undergo electrophilic irreversible covalent interaction with the
cysteine residue (Cys-147) at the active site (Fig. 1) [2,7,19].Fig. 1. The structure and inhibitory effect oAlthough the covalent binding can provide strong irreversible inhi-
bition, the electrophilic nature of CVB3 3Cpro inhibitors increase
the off-target safety risks by the possibility of interacting with host
cysteine proteases [20]. Therefore, critical unmet needs in the ﬁeld
of the discovery of allosteric reversible inhibitors against CVB3
3Cpro with reduced side effects.
Herein, we report the ﬁrst discovery of a non-competitive inhi-
bitor of CVB3 3Cpro that interacts with a putative allosteric binding
site through the screening of a drug compound library intended to
explore a new chemical class of CVB3 3Cpro inhibitors. We also pre-
sent studies on enzyme kinetics and molecular docking for the
characterization of the inhibitor.
2. Materials and methods
2.1. Expression and puriﬁcation of CVB3 3Cpro
TheCVB33Cpro genewas transformed into thepTYB12vector and
expressed in Escherichia coli strain BL21 (DE3). The CVB3 3Cpro was
puriﬁedbychitin columnchromatographyusing the IMPACTsystem
(NewEnglandBio Labs, Beverly,MA) [21]. The identity of CVB3 3Cpro
was conﬁrmed by sodium dodecyl sulphate-polyacrlamide gel elec-
trophoresis (SDS-PAGE), based on its size of almost 22kDa. Puriﬁed
CVB3 3Cpro was maintained in HEPES buffer (20 mM HEPES,
100 mMNaCl, 1 mMEDTA, 1 mMDTT (pH7.9) and 5% (v/v) glycerol)
at 20 C for an enzyme-based assay.
2.2. FRET-based enzyme assay and screening of compound library
The enzyme assays were performed in 96-well microplates with
overall reaction volumes of 100 lL comprising 50 lL 2 reaction
buffer (80 mM Tris–HCl, 2 mM DTT, 0.2% IGEPAL), 45 lL water,f various inhibitors against CVB3 3Cpro.
Scheme 1. Reagents and conditions: (a) hydrazine hydrate(excess amount), MeOH, 40 C, 12 h, 80% yield; (b) EtOH, 40 C, 8 h, 70–80% yield; (c) 0.5 N TFA in DCM, rt 1 h,
60–70% yield; (d) 20% TFA in DCM, rt, 2 h, 70–75% yield; (e) Pd/C, H2 gas MeOH, rt, 1 h, 40–50% yield.
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dimethyl sulfoxie (DMSO) of various compounds (ﬁnal concentra-
tions of compounds and DMSO are 10 lM and 1%, respectively) and
3 lL substrate peptide (1 mM concentration). The compounds and
enzymes were incubated for 5 min in the reaction solution at 25 C,
and the reactions were initiated by the addition of a ﬂuorogenic
substrate (Nma-EALFQGPPVK-Dnp-rrr-NH2/C83H126N28O21, 97%
purity) for CVB3 3Cpro, which was purchased from Anygen
(Jangseong, Republic of Korea). The ﬂuorescence values were mea-
sured at 340 nm (excitation) and 440 nm (emission) and recorded
in relative ﬂuorescence units (RFUs). Reactions were incubated at
35 C and monitored every 10 min by a spectroﬂuorometer (Bio
Tek Instrument Inc., USA) for 2 h.
Two thousand drug-like compounds (provided by LG Life
Science Ltd., Daejeon, Republic of Korea) were screened at 10 lM
on a FRET-based enzyme assay. The 12 selected hit compounds
were further screened at 5 lM, and after measuring the IC50 values
which was determined by the series of compound concentrations
(0–10 lM ﬁnal concentration at 3-fold dilution) and calculated
by SIGMAPLOT program (SPSS, San Diego, CA, USA). Finally, one
compound (Benserazide, 4; IC50 value = 2.4 lM) was selected as a
hit compound.
2.3. Enzyme kinetics study and reversibility test
An enzyme kinetics experiment was performed using the fol-
lowing method. CVB3 3Cpro was mixed with different concentra-
tions of Benserazide (4) (0–10 lM) in a ﬁnal volume of 97 lL for
5 min at 25 C. Each mixture was placed into a 96-well microplate
in triplicate. Three microliters of different concentrations of ﬂuoro-
genic substrates (0–400 lM) were also added into each respective
well. The reactions were incubated at 35 C, and the enzyme activ-
ities were monitored every 10 min by a spectroﬂuorometer (Bio
Teck Instrument Inc., USA) over a period of 2 h. Initial velocities
were determined from the linear section of the Michaelis–
Menten plot. The data were easily ﬁtted by the SIGMAPLOT pro-
gram (SPSS, San Diego, CA, USA).
The reversibility of inhibition was determined by measuring the
recovery of enzymatic activity after a large and rapid dilution of
the enzyme-inhibitor complex. The 50-fold concentration of the
IC50 values of inhibitors (Benserazide (4) and compound 3) with
the enzyme were pre-incubated for 30 min (equilibration time)
at 35 C. Then, the mixtures were diluted 50-fold with the reaction
buffer containing the ﬂuorogenic substrate (50 lM) to initiate the
enzyme reaction. The enzyme activities were monitored every
5 min by a spectroﬂuorometer (Bio Teck Instrument Inc., USA) over
a period of 2 h. Reversibility plot was ﬁtted by the SIGMAPLOT
program (SPSS, San Diego, CA, USA).2.4. In silico prediction of binding site and molecular docking study
A molecular docking study of Benserazide (4) was performed
based on the X-ray crystal structures of CVB3 3Cpro (PDB code:
2ZU3) and DOPA-decarboxylase (PDB code: 1JS3). An allosteric
binding site for the non-competitive inhibitor Benserazide (4)
was sought through the detection of cavities using the eraser algo-
rithm method. A possible allosteric binding site was found, and a
molecular docking study on this site was performed using
CDOKER, a CHARMm forceﬁeld-based docking tool from
Discovery Studio 3.5 (Accelrys Inc., San Diego, CA, USA). The pro-
cess of the CDOKER workﬂow was followed by using
high-temperature molecular dynamics to ﬁnd possible ligand con-
formations, random rotation of ligand in the rigid receptors;
grid-based simulated annealing; and full energy minimization.
The outputs of the reﬁned ligand poses were sorted by CDOKER
energy.
2.5. Synthesis and enzyme inhibitory effects of Benserazide (4)
derivatives
The 2,3,4-trihydroxybenzyl moiety of Benserazide (4) was
replaced by (b–f) di-hydroxy benzyl, mono-hydroxy benzyl (g–i)
and benzyl moieties (j) following the synthetic procedure
illustrated in Scheme 1. Those benserazide derivatives were syn-
thesized starting from 3-(tert-butyl) 4-methyl 2,2-dimethyloxazoli
dine-3,4-dicarboxylate, which was reacted with hydrazine
hydrated (excess amount) in methanol to yield compound 5.
Conjugation reactions of compound 5 with various hydroxyben-
zaldehydes (6a–j), removal of the acetonide (7a–j) and subsequent
deprotection of the Boc groups afforded hydrazone derivatives, 8a–
j. The ﬁnal compounds (9a–j) were synthesized from 8a–j by
hydrogenation. The inhibitory effects of Benserazide derivatives
against CVB3 3Cpro are summarized in Table 1.
3. Results and discussion
3.1. Hit compounds from library screening
A screening of 2000 drug-like compounds in a library using a
FRET-based enzyme assay of CVB3 3Cpro identiﬁed initial 12 hit
compounds, and we selected Benserazide (4) as a ﬁnal effective
compound with an IC50 value of 2.4 lM against CVB3 3Cpro.
Benserazide (4) is a commercial drug developed by Roche for the
management of Parkinson’s disease in combination with L-DOPA
(levodopa) as co-beneldopa (BAN), which is unable to cross the
blood-brain barrier. Thus, the drug peripherally inhibits aromatic
L-amino acid decarboxylase (AADC) or DOPA decarboxylase [22].
Table 1
% Inhibition at 50 lM or IC50 value contained various substituted benzyl moiety
compounds (8a–j, 9a–j) tested against CVB3 3Cpro.
Compd R 8 9
% Inhibition 50 lM or
(IC50)
% Inhibition 50 lM or
(IC50)
a (2.72 lM) (2.40 lM)
b N.A. N.A.
c N.A. N.A.
d N.A. N.A.
e 55.9% 56.2%
f N.A. N.A.
g N.A. N.A.
h N.A. N.A.
i N.A. N.A.
j N.A. N.A.
N.A.: no activity.
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Because the structure of Benserazide (4) is quite different from
that of known inhibitors such as 1–3 acting at the active site of
CVB3 3Cpro, we performed enzyme kinetics studies to determine
the mechanism of the inhibition of Benserazide (4) against CVB3
3Cpro. The effects of Benserazide (4) on the enzyme kinetics of
CVB3 3Cpro are illustrated in Fig. 2. In the Michaelis–Menten plot
(Fig. 2a), the Vmax values are reduced in the presence of
Benserazide (4) in a concentration-dependent manner without a
change in the Km value (64.5 lM), suggesting that Benserazide
(4) should be a non-competitive inhibitor. The Lineweaver–Burk
plot (Fig. 2b) of 1/[S] versus 1/V (1/RFUmin1) further conﬁrmed
the characteristics of non-competitive inhibition, showing a series
of lines converging at the same point on the x(1/[S]) axis (1/Km).
As shown in Fig. 2c, the Dixon plot of [I] versus 1/V (1/RFUmin1)
also resulted in a family of straight lines with the same x-axis inter-
cept, reﬂecting non-competitive inhibition [23] against CVB3 3Cpro,
and the Ki value was calculated as 4.7 lM from this ﬁgure [24].
As explained in the introduction, certain known non-
competitive inhibitors act at the active site of CVB3 3Cpro by cova-
lent interactions. However, Benserazide (4) has no electrophilic
functional group for covalent interactions; therefore, an allosteric
binding site for the Benserazide (4) should exist. To further conﬁrm
the reversible allosteric inhibition mechanism of Benserazide (4), a
reversibility test was performed with a conventional protocol
using large and rapid dilution of inhibitor. As shown in Fig. 2d,
the partial inhibition from the condition of full inhibition with high
concentration of inhibitors, Benserazide (4) (50-fold concentration
of IC50 value) suggested that the mode of enzyme inhibitory
activity of benserazide displayed a reversible pattern, while and
an irreversible inhibitor, compound 3 showed a typical irreversible
pattern of enzyme inhibition.
3.3. In silico search for a putative allosteric binding site and molecular
docking study of compound 4 (Benserazide) and its analogs
Therefore, we further pursued the determination of a novel
putative allosteric binding site of CVB3 3Cpro using an in silico study.
Among a few cavities that were detected using the eraser algorithm
method available in commercial in silico software (Discovery Studio
3.5; Accelrys Inc., San Diego, CA), the putative allosteric binding site
most ﬁtted to the size of Benserazide (4) was selected, which was
positioned opposite the active site (Fig. 3a) and was composed of
Arg13, Ser16, Asn50, Arg79, Glu81 and Arg84 residues (Fig. 3b).
The bindingmode Benserazide (4) 4 and its derivatives in this bind-
ing pocket were investigated by amolecular docking study (Fig. 3c–
f). It is speculated that (1) 2-, 3- and 4- hydroxyl groups of com-
pound Benserazide (4) may interact by hydrogen bonding with
the side chains of Arg79 and Glu81, the side chain of Asn50, and
the carbonyl oxygen of the Ser16 back bone, respectively; (2) the
carbonyl oxygen of Benserazide (4) may interact with the guanidine
moiety of Arg84; and (3) the -OH, and -NH2 groups of Benserazide
(4) may also form hydrogen bonds with the guanidine moiety of
Arg13 (Fig. 3c; CDOKER energy (Kcalmol1): 34.23). The binding
mode of compound 8a, was very similar to that of Benserazide (4)
(Fig. 3d; CDOKER energy: 31.95); the compound also exhibits an
inhibitory effect (IC50 = 2.72 lM) similar to that of Benserazide
(4). In the case of di-hydroxy benzyl (b–f), mono-hydroxy benzyl
Fig. 2. Inhibitory mechanism study of 4 (Benserazide) by enzyme kinetic and reversibility studies. (a) Michaelis–Menten plot. In the presence of various concentrations of
substrate and inhibitor, CVB3 3Cpro activity was measured by ﬂuorescence. The x-axis is the substrate concentration, and the y-axis is the CVB3 3Cpro activity (RFU min1).
Each plot describes different inhibitor concentrations 0 lM (d), 2.5 lM (4), 5.0 lM (j), 7.5 lM (s), and 10 lM (.). (b) In the Lineweaver–Burk plot, the Benserazide (4)
concentration was set to 0 lM (d), 2.5 lM (4), 5.0 lM (j), 7.5 lM (s), and 10 lM (.). The x-axis is 1/substrate concentration and the y-axis is the 1/CVB3 3Cpro activity (1/
RFU min1). (c) In the Dixon plot, the substrate concentration was set to 30 lM (d), 150 lM (j), and 300 lM (5). The x-axis is the inhibitor concentration, and the y-axis is
the 1/CVB3 3Cpro activity (1/RFU min1). (d) The reversibility plot, the x-axis is time and the y-axis is product (ﬂuorescence). Benserazide concentration (4) was set 2.5 lM
and compound 3 concentration (d) was set 150 nM.
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enzyme inhibitory activity was completely lost, and the binding
modes of those analogs (9e and 9l) suggest that decreased hydro-
gen bonding interactions (Fig. 3e; CDOKER energy: 25.46 and
Fig. 3f; CDOKER energy: 24.73) compared to those of compounds
4 or 8a (Fig. 3c and d) may have detrimental effects on the enzyme
inhibitory activity. Therefore, the 2,3,4-trihydroxybenzyl moiety
may be critically important for the binding to evoke the inhibition
of enzyme catalysis.
3.4. Comparing the binding mode of Benserazide (4) at CVB3 3Cpro and
DOPA-decarboxylase using In silico molecular docking study
Since Benserazide (4) is a potent inhibitor of DOPA decarboxy-
lase, we analyzed the possible binding mode of Benserazide in
DOPA decarboxylase by docking study. As shown in Fig. 4b, only
one phenolic hydroxyl group of benserazide might be interacted
with Lys303, which is interacted with the hydrazine moiety of
carbiDOPA [Fig. S1; in Supplementary Information]. In addition,
the serine moiety of benserazide was detected to form hydrogen
bonding with Ser193 via water molecules as the carboxylate
groups of carbiDOPA do the similar interaction. It seems that theimportant binding moieties of benserazide might be different in
between CVB3 3C protease (Fig. 4a) and DOPA decarboxylase
(Fig. 4b), which are the tri-hydroxyl groups and serine group,
respectively. Therefore, modiﬁcations of serine moiety of benser-
azide such as substitutions of the amine and hydroxyl groups or
changing to non-polar groups, may provide selective inhibition of
CVB3 3C protease to avoid potential side effects, which may be
caused by the inhibition of decarboxylase enzymes.
4. Conclusion
Herein, we reported that a novel non-competitive CVB3 3Cpro
inhibitor Benserazide (4), a known anti-Parkinson’s disease drug,
was discovered through screening using a FRET-based enzyme
assay. The mechanism of enzyme inhibition and the binding mode
of Benserazide (4) and its derivatives were characterized by
enzyme kinetics and in silico molecular docking studies. These
studies demonstrate that Benserazide (4) is a non-competitive
inhibitor that interacts with a putative allosteric binding site, and
the 2,3,4-trihydroxybenzyl moiety of Benserazide (4) is the most
important to the inhibitory action against CVB 3Cpro. These results
suggest that new therapeutic strategies targeting the newly found
Fig. 3. In silico binding site prediction and molecular docking study. (a) Overall structure of CVB3 3Cpro (PDB code: 2ZU3); each known active site and putative allosteric active
site is highlighted with red- and blue-colored spheres, respectively. (b) The expanded putative allosteric binding site; it is composed of Arg13, Ser16, Asn50, Arg79, Glu81, and
Arg84 residues. (c) and (d) Binding modes of 4 (gray), 8a (green). (e and f) Binding modes of 9e (purple), 9l (yellow). The hydrogen bond interactions are represented by green
dotted lines. Important amino acids are described and labeled in green.
1800 B.-K. Kim et al. / FEBS Letters 589 (2015) 1795–1801
Fig. 4. Comparing the binding mode of Benserazide (4) at CVB3 3Cpro and DOPA-
decarboxylase. (a) The binding mode of Benserazide (4) at CVB3 3Cpro and (b)
DOPA-decarboxylase. The hydrogen bond interactions are represented by green
dotted lines. Important amino acids are described and labeled in green. The surface
of binding site was highlighted in hydrogen donor (purple) and acceptor (green).
B.-K. Kim et al. / FEBS Letters 589 (2015) 1795–1801 1801putative allosteric binding site of CVB 3Cpro could be applied for the
development of non-competitive inhibitors.
Acknowledgements
This research was supported by a Grant of Basic Science
Research Program through the National Research Foundation of
South Korea (NRF) funded by the Ministry of Education, Science
and Technology (Grant No. NRF-2013R1A1A2059917 and
NRF-2014M349A9073788).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2015.05.
027.
References
[1] Yuan, J. et al. (2006) Inhibition of coxsackievirus B3 in cell cultures and in mice
by peptide-conjugated morpholino oligomers targeting the internal ribosome
entry site. J. Virol. 80, 11510–11519.
[2] De Palma, A.M., Vliegen, I., De Clercq, E. and Neyts, J. (2008) Selective
inhibitors of picornavirus replication. Med. Res. Rev. 28, 823–884.[3] Feldman, A.M. and McNamara, D. (2000) Myocarditis. N. Engl. J. Med. 343,
1388–1398.
[4] D’Ambrosio, A., Patti, G., Manzoli, A., Sinagra, G., Di Lenarda, A., Silvestri, F. and
Di Sciascio, G. (2001) The fate of acute myocarditis between spontaneous
improvement and evolution to dilated cardiomyopathy: a review. Heart 85,
499–504.
[5] Chau, D.H., Yuan, J., Zhang, H., Cheung, P., Lim, T., Liu, Z., Sall, A. and Yang, D.
(2007) Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death
through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/NAT1.
Apoptosis 12, 513–524.
[6] Kim, B.K., Kim, J.H., Kim, N.R., Lee, W.G., Lee, S.D., Yun, S.H., Jeon, E.S. and Kim,
Y.C. (2012) Development of anti-coxsackievirus agents targeting 3C protease.
Bioorg. Med. Chem. Lett. 22, 6952–6956.
[7] Lee, E.S. et al. (2007) Development of potent inhibitors of the coxsackievirus
3C protease. Biochem. Biophys. Res. Commun. 358, 7–11.
[8] Zell, R., Markgraf, R., Schmidtke, M., Gorlach, M., Stelzner, A., Henke, A.,
Sigusch, H.H. and Gluck, B. (2004) Nitric oxide donors inhibit the
coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells,
and signs of myocarditis in virus-infected mice. Med. Microbiol. Immunol. 193,
91–100.
[9] Binford, S.L., Maldonado, F., Brothers, M.A., Weady, P.T., Zalman, L.S., Meador
3rd, J.W., Matthews, D.A. and Patick, A.K. (2005) Conservation of amino acids
in human rhinovirus 3C protease correlates with broad-spectrum antiviral
activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.
Antimicrob. Agents Chemother. 49, 619–626.
[10] Kuo, R.L., Kung, S.H., Hsu, Y.Y. and Liu, W.T. (2002) Infection with enterovirus
71 or expression of its 2A protease induces apoptotic cell death. J. Gen. Virol.
83, 1367–1376.
[11] Weng, K.F., Li, M.L., Hung, C.T. and Shih, S.R. (2009) Enterovirus 71 3C protease
cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS
Pathog. 5, e1000593.
[12] Li, M.L., Hsu, T.A., Chen, T.C., Chang, S.C., Lee, J.C., Chen, C.C., Stollar, V. and
Shih, S.R. (2002) The 3C protease activity of enterovirus 71 induces human
neural cell apoptosis. Virology 293, 386–395.
[13] Wu, K.X., Ng, M.M. and Chu, J.J. (2010) Developments towards antiviral
therapies against enterovirus 71. Drug Discov. Today 15, 1041–1051.
[14] Lall, M.S., Jain, R.P. and Vederas, J.C. (2004) Inhibitors of 3C cysteine
proteinases from Picornaviridae. Curr. Top. Med. Chem. 4, 1239–1253.
[15] Ramajayam, R., Tan, K.P., Liu, H.G. and Liang, P.H. (2010) Synthesis and
evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease
inhibitors. Bioorg. Med. Chem. 18, 7849–7854.
[16] Barnard, D.L. (2006) Current status of anti-picornavirus therapies. Curr.
Pharm. Des. 12, 1379–1390.
[17] Lee, C.C. et al. (2009) Structural basis of inhibition speciﬁcities of 3C and 3C-
like proteases by zinc-coordinating and peptidomimetic compounds. J. Biol.
Chem. 284, 7646–7655.
[18] Kuo, C.J., Liu, H.G., Lo, Y.K., Seong, C.M., Lee, K.I., Jung, Y.S. and Liang, P.H.
(2009) Individual and common inhibitors of coronavirus and picornavirus
main proteases. FEBS Lett. 583, 549–555.
[19] Webber, S.E. et al. (1996) Design, synthesis, and evaluation of nonpeptidic
inhibitors of human rhinovirus 3C protease. J. Med. Chem. 39, 5072–5082.
[20] Baxter, A. et al. (2011) Non-covalent inhibitors of rhinovirus 3C protease.
Bioorg. Med. Chem. Lett. 21, 777–780.
[21] Cordingley, M.G., Register, R.B., Callahan, P.L., Garsky, V.M. and Colonno, R.J.
(1989) Cleavage of small peptides in vitro by human rhinovirus 14 3C protease
expressed in Escherichia coli. J. Virol. 63, 5037–5045.
[22] Shen, H., Kannari, K., Yamato, H., Arai, A. and Matsunaga, M. (2003) Effects of
benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-
amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-
lesioned rats. Tohoku J. Exp. Med. 199, 149–159.
[23] Ryu, Y.B. et al. (2010) Biﬂavonoids from Torreya nucifera displaying SARS-CoV
3CL(pro) inhibition. Bioorg. Med. Chem. 18, 7940–7947.
[24] Nguyen, T.T., Ryu, H.J., Lee, S.H., Hwang, S., Breton, V., Rhee, J.H. and Kim, D.
(2011) Virtual screening identiﬁcation of novel severe acute respiratory
syndrome 3C-like protease inhibitors and in vitro conﬁrmation. Bioorg. Med.
Chem. Lett. 21, 3088–3091.
[25] Costenaro, L. et al. (2011) Structural basis for antiviral inhibition of the main
protease, 3C, from human enterovirus 93. J. Virol. 85, 10764–10773.
[26] Lu, G. et al. (2011) Enterovirus 71 and coxsackievirus A16 3C proteases:
binding to rupintrivir and their substrates and anti-hand, foot, and mouth
disease virus drug design. J. Virol. 85, 10319–10331.
[27] Tan, J. et al. (2013) 3C protease of enterovirus 68: structure-based design of
Michael acceptor inhibitors and their broad-spectrum antiviral effects against
picornaviruses. J. Virol. 87, 4339–4351.
[28] Mosimann, S.C., Cherney, M.M., Sia, S., Plotch, S. and James, M.N. (1997)
Reﬁned X-ray crystallographic structure of the poliovirus 3C gene product. J.
Mol. Biol. 273, 1032–1047.
[29] Matthews, D.A. et al. (1999) Structure-assisted design of mechanism-based
irreversible inhibitors of human rhinovirus 3C protease with potent antiviral
activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U.S.A. 96,
11000–11007.
[30] Cui, S. et al. (2011) Crystal structure of human enterovirus 71 3C protease. J.
Mol. Biol. 408, 449–461.
